Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

I-MIBG imaging for detection of anthracycline-induced cardiomyopathy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Laursen, Adam H ; Thune, Jens Jakob ; Hutchings, Martin ; Hasbak, Philip ; Kjaer, Andreas ; Elming, Marie B ; Ripa, Rasmus S. / I-MIBG imaging for detection of anthracycline-induced cardiomyopathy. I: Clinical Physiology and Functional Imaging. 2018 ; Bind 38, Nr. 2. s. 176-185.

Bibtex

@article{98f108f3cd454a88b8409bac8fba8ed7,
title = "I-MIBG imaging for detection of anthracycline-induced cardiomyopathy",
abstract = "Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated.123I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of123I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of123I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.",
keywords = "Journal Article, Review",
author = "Laursen, {Adam H} and Thune, {Jens Jakob} and Martin Hutchings and Philip Hasbak and Andreas Kjaer and Elming, {Marie B} and Ripa, {Rasmus S}",
note = "{\textcopyright} 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.",
year = "2018",
month = mar,
doi = "10.1111/cpf.12419",
language = "English",
volume = "38",
pages = "176--185",
journal = "Clinical Physiology and Functional Imaging",
issn = "1475-0961",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - I-MIBG imaging for detection of anthracycline-induced cardiomyopathy

AU - Laursen, Adam H

AU - Thune, Jens Jakob

AU - Hutchings, Martin

AU - Hasbak, Philip

AU - Kjaer, Andreas

AU - Elming, Marie B

AU - Ripa, Rasmus S

N1 - © 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated.123I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of123I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of123I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.

AB - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated.123I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of123I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of123I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.

KW - Journal Article

KW - Review

U2 - 10.1111/cpf.12419

DO - 10.1111/cpf.12419

M3 - Review

C2 - 28251781

VL - 38

SP - 176

EP - 185

JO - Clinical Physiology and Functional Imaging

JF - Clinical Physiology and Functional Imaging

SN - 1475-0961

IS - 2

ER -

ID: 52702853